Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease
Hu, Yan ; Cho, Min ; Sachdev, Pallavi ; Dage, Jeffrey ; Hendrix, Suzanne ; Hansson, Oskar LU
; Bateman, Randall J.
and Hampel, Harald
(2024)
In Med
5(10).
p.1206-1226
- Abstract
Clinical management and therapeutics development for Alzheimer's disease (AD) have entered a new era, with recent approvals of monoclonal antibody therapies targeting the underlying pathophysiology of the disease and modifying its trajectory. Imaging and fluid biomarkers are becoming increasingly important in the clinical development of AD therapeutics. This review focuses on the evidence of fluid biomarkers from recent amyloid-β-targeting clinical trials, summarizing biomarker data across 12 trials. It further proposes a simple framework to put biomarker guidance in the context of amyloid-pathway-targeted disease modification, delineates factors that impact biomarker data in clinical trials, and highlights knowledge gaps and future... (More)
Clinical management and therapeutics development for Alzheimer's disease (AD) have entered a new era, with recent approvals of monoclonal antibody therapies targeting the underlying pathophysiology of the disease and modifying its trajectory. Imaging and fluid biomarkers are becoming increasingly important in the clinical development of AD therapeutics. This review focuses on the evidence of fluid biomarkers from recent amyloid-β-targeting clinical trials, summarizing biomarker data across 12 trials. It further proposes a simple framework to put biomarker guidance in the context of amyloid-pathway-targeted disease modification, delineates factors that impact biomarker data in clinical trials, and highlights knowledge gaps and future directions. Increased knowledge and data on biomarkers in the context of disease progression and disease modification will help to better design future AD trials and guide the clinical management of patients on AD-modifying therapies, bringing us closer to the implementation of precision medicine in AD.
(Less)
- author
- Hu, Yan
; Cho, Min
; Sachdev, Pallavi
; Dage, Jeffrey
; Hendrix, Suzanne
; Hansson, Oskar
LU
; Bateman, Randall J.
and Hampel, Harald
- organization
- publishing date
- 2024-10-11
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Med
- volume
- 5
- issue
- 10
- pages
- 21 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:39255800
- scopus:85206219713
- ISSN
- 2666-6359
- DOI
- 10.1016/j.medj.2024.08.004
- language
- English
- LU publication?
- yes
- id
- b8aa0dca-14f6-45c0-8703-72be70303086
- date added to LUP
- 2024-12-11 11:33:46
- date last changed
- 2025-07-10 04:38:39
@article{b8aa0dca-14f6-45c0-8703-72be70303086,
abstract = {{<p>Clinical management and therapeutics development for Alzheimer's disease (AD) have entered a new era, with recent approvals of monoclonal antibody therapies targeting the underlying pathophysiology of the disease and modifying its trajectory. Imaging and fluid biomarkers are becoming increasingly important in the clinical development of AD therapeutics. This review focuses on the evidence of fluid biomarkers from recent amyloid-β-targeting clinical trials, summarizing biomarker data across 12 trials. It further proposes a simple framework to put biomarker guidance in the context of amyloid-pathway-targeted disease modification, delineates factors that impact biomarker data in clinical trials, and highlights knowledge gaps and future directions. Increased knowledge and data on biomarkers in the context of disease progression and disease modification will help to better design future AD trials and guide the clinical management of patients on AD-modifying therapies, bringing us closer to the implementation of precision medicine in AD.</p>}},
author = {{Hu, Yan and Cho, Min and Sachdev, Pallavi and Dage, Jeffrey and Hendrix, Suzanne and Hansson, Oskar and Bateman, Randall J. and Hampel, Harald}},
issn = {{2666-6359}},
language = {{eng}},
month = {{10}},
number = {{10}},
pages = {{1206--1226}},
publisher = {{Elsevier}},
series = {{Med}},
title = {{Fluid biomarkers in the context of amyloid-targeting disease-modifying treatments in Alzheimer's disease}},
url = {{http://dx.doi.org/10.1016/j.medj.2024.08.004}},
doi = {{10.1016/j.medj.2024.08.004}},
volume = {{5}},
year = {{2024}},
}